Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747390 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
A Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus, sponsored by Ryan Carey.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06747390 is a Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus that is actively recruiting participants, run by Ryan Carey. The registered enrollment target is 30 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06747390, a Phase 1 study of Squamous Cell Carcinoma and Human Papilloma Virus, is actively recruiting participants, sponsored by Ryan Carey.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carcinoma (OPSCC). The primary objective of the study is to determine if intratumoral lidocaine injection is safe and causes a major pathologic treatment effect in the primary tumor following surgical resection. The secondary objectives will be to determine if intratumoral lidocaine injection improves locoregional control rates, progression-free survival, metastasis-free survival, and overall survival compared to no injection.
Conditions Studied
Interventions
- DRUG Lidocaine 1% Injectable Solution
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747390
The ClinicalTrials.gov registry entry for NCT06747390 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Ryan Carey, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lidocaine 1% Injectable Solution is the first listed.
NCT06747390 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06747390 about?
NCT06747390 is a clinical study titled "Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery". Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carci...
What is the current status of trial NCT06747390?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-04-23. Estimated completion is 2028-11-01.
What conditions does trial NCT06747390 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Human Papilloma Virus, Oropharyngeal Cancer, Oropharyngeal Squamous Cell Carcinoma (OPSCCA).
What interventions are being tested in trial NCT06747390?
The interventions under investigation include: Lidocaine 1% Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT06747390?
This trial is sponsored by Ryan Carey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747390 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
ACTIVE NOT RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Pembrolizumab in Combination With CRT for LA-SCCHN
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.